Sun Pharmaceutical Industries Limited (SUNPHARMA) Cash Flow Statement

A cash flow statement shows the actual cash a company generated and spent across operating, investing, and financing activities over a reporting period.

Sun Pharmaceutical Industries Limited, a generic pharmaceutical company, develops, manufactures, and markets branded and generic formulations, and active pharmaceutical ingredients (APIs) in India, the United States, and internationally.

Total Cash From Operating Activities Chart for Sun Pharmaceutical Industries Limited

Sun Pharmaceutical Industries Limited (SUNPHARMA) operating cash flow for FY2026 was INR 128.5B, a -8.7% change from FY2025. Sun Pharmaceutical Industries Limited's operating cash flow grew from INR 2.9B in 2004 to INR 128.5B in 2026 (4365.2% over 22 years). Operating cash flow compound annual growth rate: 5-year CAGR of 15.8%, 10-year CAGR of 6.6%, 20-year CAGR of 23.6%.

The most recent 3 years are real; the rest is blurred as a preview. Sign up free to unlock every line item, quarterly data, and the real full history. Free account: 8 years of history for 10 flagship companies. Premium: full history for 500+ companies. Premium is €10.00/month. See pricing.